moonpatrol| Warner Pharmaceuticals: Notification of approval for marketing application for benidipine hydrochloride chemical raw material

News summary

[Warner Pharmaceutical Factorymoonpatrol: Notice of approval for the listing application of benidipine hydrochloride chemical raw material] Securities Times e Company News, Warner Pharmaceutical Factory (688799) announced on the evening of May 27 that recently, the company's wholly-owned subsidiary Hunan Warner Pharmaceutical Factory Chiral Drugs Co., Ltd. Received issued by the State Drug Administrationmoonpatrol...

Newsletter text

[Warner Pharmaceutical Company: Notice of approval for listing application for benidipine hydrochloride chemical raw material] Securities Times e Company News, Warner Pharmaceutical Factory (688799) announced on the evening of May 27 that recently, Hunan Warner Pharmaceutical Factory Chiral Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received a notice of approval for listing application for benidipine hydrochloride chemical raw material issued by the State Food and Drug Administration, and issued a notice in the Drug Evaluation Center (CDE) of the State Food and Drug Administration Announcement of Registration Information on Pharmaceutical Excipients and Pharmaceutical Packaging Materials. Benidipine hydrochloride belongs to a calcium channel blocker and is mainly used to treat essential hypertension and angina pectoris.